Results 61 to 70 of about 62,474 (297)

Vision Changes After Head and Neck Cancer Treatment

Head &Neck, EarlyView.
ABSTRACT Background Literature about ocular toxicity after head and neck cancer (HNC) treatment is scarce. This study aimed to describe visual function and ocular symptoms among HNC patients. Methods The study used a cross‐sectional design. Two surveys, The National Eye Institute Visual Functioning Questionnaire (NEI‐VFQ) and an Ocular Symptom Scale ...
Hsiao‐Lan Wang, Megan Heskett, Peng Li, Laura Dreer, David Vance, Susan McCammon, Kailei Yan, Amanda Elliott   +7 more
wiley   +1 more source

Pro re nata versus fixed aflibercept regimen for neovascular age-related macular degeneration: a systematic review and meta-analysis

International Journal of Retina and Vitreous, 2022
Background Aflibercept is a relatively new anti-VEGF used to treat neovascular age-related macular degeneration (AMD). The purpose of this review is to evaluate the effect of pro re nata (PRN) and fixed regimen (bimonthly) of aflibercept injection for ...
Andi Arus Victor, Yan Martha Putri
doaj   +1 more source

A simulation tool for better management of retinal services [PDF]

, 2018
Background: Advances in the management of retinal diseases have been fast-paced as new treatments become available, resulting in increasing numbers of patients receiving treatment in hospital retinal services.
A Kotecha, A Kotecha, Aimee Verner, Andriy Danyliv, CG Owen, David Southern, Eren Demir, FG Holz, GA Lalwani, HR Wright, JA Haller, K Hatz, Karsten Kortuem, Katja Hatz, KT Tsaousis, Line Kvannli, OP Gupta, RB Rush, S Trikha, W Amoaku, Winfried Amoaku   +20 more
core   +1 more source

Indication‐Specific Dosing and Dose‐Evaluation Strategies in New Indications for Non‐Oncology Monoclonal Antibodies

The Journal of Clinical Pharmacology, EarlyView.
Abstract Compared to traditional small molecule drugs, monoclonal antibodies (mAbs) often display more complex pharmacokinetic (PK) and pharmacodynamic (PD) properties that may be impacted by disease‐specific factors. For mAbs in non‐oncology indications, where the same drug might be used for conditions involving different organ systems and/or having ...
Sherouk M. Tawfik, Fei Tang
wiley   +1 more source

QM107, a novel CD148 (RTP Type J) activating peptide therapy for treating neovascular age-related macular degeneration. [PDF]

BACKGROUND AND PURPOSE: Angiogenesis is a pathological component of neovascular age-related macular degeneration. Current therapies, although successful, are prone to high levels of patient non-response and a loss of efficacy over time, indicating the ...
Arokiasamy, S, Bainbridge, JW, Balderstone, MJM, Cristante, E, De Rossi, G, Madoo, A, Moseley, TC, Rizzi, M, Rosas, IO, Shaik, F, Tsoyi, K, Whiteford, JR   +11 more
core   +1 more source

OUTER RETINAL TUBULATION IN ADVANCED AGE-RELATED MACULAR DEGENERATION: Optical Coherence Tomographic Findings Correspond to Histology [PDF]

, 2015
PURPOSE: To compare optical coherence tomography (OCT) and histology of outer retinal tubulation (ORT) secondary to advanced age-related macular degeneration in patients and in postmortem specimens, with particular attention to the basis of the ...
Curcio, C. A., Freund, K. B., Litts, K. M., Messinger, J. D., Schaal, K. B., Zhang, Y.   +5 more
core   +2 more sources

Recent Advancements in the Treatment of Age‐Related Macular Degeneration

Med Research, EarlyView.
ABSTRACT Age‐related macular degeneration (AMD) is a prevalent cause of visual impairment and blindness among the elderly. AMD can be categorized into two subtypes: “wet” and “dry.” Current treatments for wet AMD mainly involve anti‐vascular endothelial growth factor (VEGF) drugs, and there are three U.S.
Shan Liu, Danyang Lv, Junran Sun, Huixun Jia, Fang Zheng, Felipe Pereira, Siddharth Narendran, Zhenyu Dong, Haiyun Liu, Shunxiang Gao, Peirong Huang   +10 more
wiley   +1 more source

An update on the pharmacotherapy of neovascular age-related macular degeneration

Expert Opinion on Pharmacotherapy, 2013
Neovascular age-related macular degeneration (AMD) is currently the most common cause of legal blindness in industrialized countries. The advent of pharmacotherapy with intravitreal VEGF inhibitors has greatly improved outcomes for the treatment of this disease.The present review is divided into two major sections: the period prior to the use of anti ...
Sarah Mrejen, Roberto Gallego-Pinazo, K. Bailey Freund   +2 more
openaire   +4 more sources

Preliminary study on electrophysiological changes after cellular autograft in age-related macular degeneration [PDF]

, 2014
Background: Evolving atrophic macular degeneration represents at least 80% of all macular degenerations and is currently without a standardized care. Autologous fat transplantation (AFT) efficacy was demonstrated by several studies, since these cells are
C., Limoli, M. U., Morales, Nebbioso, Marcella, P. G., Limoli, Vingolo, Enzo Maria   +4 more
core   +1 more source

Current Advances in the Combination of Fatty Acids and Resveratrol to Fight Ocular Diseases

Molecular Nutrition &Food Research, EarlyView.
Graphical abstract illustrating the effects of Resvega administration on choroidal neovascularization and resveratrol metabolism in the retina. The diagram illustrates that oral administration of Resvega leads to a decrease in choroidal neovascularization.
Dominique Delmas, Maude Perus, Virginie Aires, François Hermetet   +3 more
wiley   +1 more source